Arvinas, Inc.

ARVN

US04335A1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-09 pm EDT			5-day change	1st Jan Change
8.230 ^USD	+2.62%		+7.86%	-57.07%

Jul. 09	Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as President	CI
Jul. 09	Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as Chief Executive Officer	CI

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

Published on 05/31/2025 at 08:01, updated on 05/31/2025 at 12:28

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Arvinas, Inc.

Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as President	Jul. 09	CI
Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as Chief Executive Officer	Jul. 09	CI
Arvinas' CEO to Retire; Search for Successor Begins	Jul. 09	MT
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 3000 Value Index	Jun. 30	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 2500 Value Index	Jun. 30	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025	Jun. 30	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 2000 Value Index	Jun. 30	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 3000E Value Index	Jun. 30	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 2000 Value Benchmark	Jun. 29	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 2500 Value Benchmark	Jun. 29	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 3000 Value Benchmark	Jun. 29	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell 3000E Value Benchmark	Jun. 29	CI
Arvinas, Inc.(NasdaqGS:ARVN) added to Russell Small Cap Comp Value Benchmark	Jun. 29	CI
Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc.	Jun. 17	CI
Arvinas, Inc. Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress	Jun. 13	CI
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma	Jun. 13	MT
Arvinas, Inc. - Special Call	Jun. 12
Arvinas, Inc. Announces Resignation of Ian Taylor as President of Research and Development, Effective June 6, 2025	Jun. 06	CI
Sector Update: Health Care Stocks Advance Premarket Friday	Jun. 06	MT
Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer	Jun. 06	DJ
Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer	Jun. 06	CI
Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment	Jun. 06	MT
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer	Jun. 06	RE
Wall Street Monitors Global Trade Situation as US Equity Futures Move Lower Pre-Bell	Jun. 02	MT

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Employees

430

Sector

Biotechnology & Medical Research

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company